Atlas Trials

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AML

Clinical trial NCT04842370 · UNKNOWN

Trial details

NCT number
NCT04842370
Sponsor
Seoul National University Hospital
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Relapsed or Refractory Acute Myeloid Leukemia
Start date
2020-06-08
Primary completion
2022-05-21
Enrollment
42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.